TCR2 Therapeutics (TCRR) to Offer 6M Common Shares

TCR2 Therapeutics Inc. (Nasdaq: TCRR) has commenced an underwritten public offering of 6,000,000 shares of its common stock. TCR2 also intends to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock. All of the shares in the proposed offering are to be sold by TCR2. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

Jefferies, SVB Leerink, Piper Sandler and BMO Capital Markets are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey is acting as co-manager for the offering.

TCR2 intends to use the net proceeds of the offering to advance its clinical and earlier stage programs and for research and development, working capital and general corporate purposes.

You May Also Be Interested In

• BMO Capital Upgrades Casey's General Stores (CASY) to Outperform, 'Opportunity Knocks'
• Bending Spoons closes IPO, raises ~$954M on Nasdaq
• Veru sets up $21.8M at-the-market stock offering